Genome editing in hemoglobinopathies
EHA Learning Center, Mitch Weiss, 184460
Biological and clinical relevance of fibrin clot structure
EHA Learning Center, Nicola Mutch, 184464
Fertility preservation in females
EHA Learning Center, Marie-Madeline Dolmans, 192906
TARGETED SINGLE CELL SEQUENCING TO IDENTIFY MUTATIONAL HIERARCHY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Jolien De Bie, 181438
BCL-2 INHIBITION AS NEW THERAPEUTIC OPPORTUNITY FOR RPL10 R98S MUTANT PEDIATRIC T-ALL
EHA Learning Center, Kim Kampen, 181439
TRANSLATOME ANALYSIS OF THE T-ALL ASSOCIATED RIBOSOMAL PROTEIN L10 R98S MUTATION REVEALS ALTERED SERINE METABOLISM
EHA Learning Center, Laura Fancello, 181440
REPOSITIONING EXISTING DRUGS AS NOVEL THERAPEUTICS: OXIDATIVE STRESS AS A TARGET FOR HIGH-RISK LEUKAEMIA IN CHILDREN
EHA Learning Center, Mawar Karsa, 181441
TP53 MUTATIONS DISRUPTING DNA BINDING LEAD TO CHEMOTHERAPY RESISTANCE IN ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Malwine Pogodzinski, 181442
GENETIC ACTIVATION AND THERAPEUTIC TARGETING OF PIM1 IN T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA
EHA Learning Center, Renate De Smedt, 181443
IL-7 FLEXIBLY REGULATES AUTOPHAGY-DEPENDENT VIABILITY OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELLS
EHA Learning Center, Daniel Ribeiro, 181444
PRECLINICAL ACTIVITY OF ENTOSPLETINIB IN CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Sarah Tasian, 181445
PHARMACOLOGICAL ACTIVITY OF CB-103 - AN ORAL PAN-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION
EHA Learning Center, Dirk Weber, 181446
IKZF1Δ4-7 CAN BE EASILY SCREENED BY PCR BUT DOES NOT PREDICT OUTCOME IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA; DATA FROM 490 PATIENTS ENROLLED ON THE UKALL14 TRIAL.
EHA Learning Center, Rachel Mitchell, 181447
PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE DETECTED BY MLL FUSION GENE TRANSCRIPTS IN INFANT ACUTE LYMPHOBLASTIC LEUKEMIA. UPDATED RESULTS OF 76 PATIENTS ENROLLED INTO MLL-BABY STUDY
EHA Learning Center, Grigory Tsaur, 181448
PRO-T CELL ALL/LBL: AN ULTRA-HIGH RISK CD2-NEGATIVE DISEASE SUBTYPE IN ADULTS DEFINED BY FLOW CYTOMETRY
EHA Learning Center, Beata Ostrowska, 181449
CLINICAL SIGNIFICANCE OF END OF INDUCTION MINIMAL RESIDUAL DISEASE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMPLETE REMISSION AFTER A SINGLE CHEMOTHERAPY COURSE
EHA Learning Center, Renato , 181450
RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA
EHA Learning Center, Nick Morley, 181451
CLINICAL OUTCOMES OF ELDERLY ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA - A SINGLE INSTITUTION EXPERIENCE
EHA Learning Center, Kevin Miller, 181452
MANAGEMENT AND OUTCOME OF ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED AT THE “SAPIENZA” UNIVERSITY BETWEEN 1996 AND 2016
EHA Learning Center, Sabina Chiaretti, 181453
THE TETRASPANIN CD9 IS A PROGNOSTIC MARKER FOR PREDICTING SURVIVAL OUTCOMES OF PEDIATRIC B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Kam Tong Leung, 181454
PEDIATRIC MLL ACUTE LEUKEMIA PATIENTS SHOW DIFFERENTIAL HDAC EXPRESSION
EHA Learning Center, Nerea Vega-Garcia, 181455
MINIMAL DISSEMINATED DISEASE DETECTION BY FLOWCYTOMETRIC IMMUNOPHENOTYPING IN T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA
EHA Learning Center, Ganesh Kumar Viswanathan, 181456
INOTUZUMAB OZOGAMICIN IN COMBINATION WITH LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AS FRONTLINE THERAPY FOR OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE I/II TRIAL
EHA Learning Center, Nicholas Short, 181457
RECURRENT MYB REARRANGEMENT IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
EHA Learning Center, KYOGO SUZUKI, 181458
BRANCHED CHAIN AMINO ACID METABOLISM REGULATES ALPHA-KETOGLUTARATE HOMEOSTASIS RESEMBLING MUTANT-IDH DRIVEN DNA HYPERMETHYLATION IN AML
EHA Learning Center, Simon Raffel, 181459
NUCLEAR RE-LOCALIZATION OF NPM1C+ INDUCES DIFFERENTIATION AND CELL GROWTH ARREST
EHA Learning Center, Lorenzo Brunetti, 181460
THE LONG NON-CODING RNA HOXB-AS3 REGULATES RIBOSOMAL BIOGENESIS IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA
EHA Learning Center, Dimitrios Papaioannou, 181461
A DUAL BH3-MIMETIC APPROACH TARGETING BOTH BCL-2 AND MCL1 IS HIGHLY EFFICACIOUS AND WELL-TOLERATED IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Donia Moujalled, 181462
THE PMLC62A/C65A KNOCK-IN MOUSE MODEL PROVIDES EVIDENCE FOR THE ROLE OF NUCLEAR BODY DISRUPTION IN THE PATHOGENESIS OF ACUTE PROMYELOCYTIC LEUKEMIA
EHA Learning Center, Edwige VOISSET, 181463
DECIPHERING THE ONCOGENIC NETWORK OF PRC2 LOSS GUIDED LEUKEMOGENISIS
EHA Learning Center, Jan-Henning Klusman, 181464
ACUTE MYELOID LEUKEMIA EVOLUTION CAN BE RECONSTRUCTED BY ANALYSIS OF NON-LEUKEMIC CELLULAR SUBCOMPARTMENTS AND MULTI-LINEAGE ENGRAFTED MICE
EHA Learning Center, Borhan Saeed, 181466
THE ESSENTIAL ROLE OF THE ENHANCERS OF POLYCOMB EPC1 AND EPC2 IN MLL-AF9 ACUTE MYELOID LEUKAEMIA IS A ‘COMPLEX' STORY
EHA Learning Center, Niamh Mannion, 181467
STROMA-DERIVED FACTORS STIMULATE JAK/STAT SIGNALING IN AML CELLS RESULTING IN RESISTANCE TO BCL2 INHIBITOR VENETOCLAX
EHA Learning Center, Riikka Karjalainen, 181468
IDENTIFICATION OF NOVEL GENE FUSIONS IN ACUTE MYELOID LEUKEMIA WITH COMPLEX KARYOTYPE BY TRANSCRIPTOME ANALYSIS USING RNA SEQUENCING
EHA Learning Center, Frank Rücker, 181469
H3K27ME3 LEVEL ON THE HIST1 CLUSTER: A POWERFUL EPIGENETIC BIOMARKER THAT STRATIFIES TWO GROUPS OF NPM1-MUTATED AML DIFFERING IN THEIR OUTCOME AND EXPRESSION PROFILE
EHA Learning Center, Sylvain garciaz, 181470
FUNCTIONAL ASSESSMENT OF NOVEL DIAGNOSTIC FLT3 MUTATIONS AND INHIBITION BY KINASE INHIBITORS
EHA Learning Center, Katherine Tarlock, 181471
THE BCL-2 INHIBITOR VENETOCLAX INHIBITS NRF2 ANTIOXIDANT PATHWAY ACTIVATION INDUCED BY HYPOMETHYLATING AGENTS IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Le Xuan Truong, 181473
UNRAVELING EPIGENOMIC REGULATION IN THE EVOLUTION OF RELAPSING PEDIATRIC AML
EHA Learning Center, Caroline Wiggers, 181474
MECHANISTICALLY INFORMED COMBINATIONS OF SY-1425, A POTENT AND SELECTIVE RARΑ AGONIST, WITH HYPOMETHYLATING OR ANTI-CD38 TARGETED AGENTS IN AML AND MDS
EHA Learning Center, Michael McKeown, 181475
FLT3 INHIBITION OVERCOMES RESISTANCE TO THE BCL-2 SELECTIVE ANTAGONIST, VENETOCLAX, IN FLT3-ITD MUTANT AML MODELS
EHA Learning Center, Deepak Sampath, 181476
SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA STEM CELLS BY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7
EHA Learning Center, Linda Smit, 181477
ONGOING PHASE 2 CLINICAL TRIAL OF SL-401 IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN): STAGE 1 AND STAGE 2 RESULTS
EHA Learning Center, Naveen Pemmaraju, 181478
PROGNOSTIC IMPACT OF SOMATIC MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Learning Center, Koichi Takahashi, 181479
DO EDUCATION AND INCOME AFFECT TREATMENT AND OUTCOME IN ACUTE MYELOID LEUKEMIA IN A TAX-SUPPORTED HEALTH CARE SYSTEM? A DANISH NATIONAL POPULATION-BASED COHORT STUDY
EHA Learning Center, lene granfeldt, 181480
IDENTIFICATION OF PATTERNS IN CO-OCCURRING MUTATIONS IN AML PATIENTS WITH GERMLINE AND SOMATIC RUNX1 MUTATIONS
EHA Learning Center, Uma Borate, 181481
MULTIPLE LEUKEMIC STEM CELL MARKER EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN DE NOVO ACUTE MYELOID LEUKEMIA
EHA Learning Center, Tomohiro Yabushita, 181483
NEXT GENERATION SEQUENCING TARGETED PANEL FOR MINIMAL RESIDUAL DISEASEMONITORING IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Valerie McClain, 181484
IS IT POSSIBLE TO RELIABLY DETECT CLINICALLY-RELEVANT BIALLELIC CEBPA GENE MUTATIONS USING NGS PANELS?
EHA Learning Center, Marta Fernandez-Mercado, 181485
EXPERIENCE WITH MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN AML WITH RUNX1-RUNX1T1: A STUDY ON 186 PATIENTS
EHA Learning Center, Alexander Höllein, 181486
NUMBER OF TP53 ABNORMALITIES AND THEIR CLINICAL RELEVANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Guillermo Montalban-Bravo, 181487
VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS (HMA): A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Farhad Ravandi-Kashani, 181488
ACUTE MYELOID LEUKEMIA WITH INTERMEDIATE-RISK CYTOGENETICS AND A FAVORABLE GENOTYPE: PROGNOSTIC FACTORS AND RESULTS IN PATIENTS TREATED ACCORDING THE SPANISH CETLAM PROTOCOLS.
EHA Learning Center, Jorge Sierra, 181489
GMI-1271, A POTENT E-SELECTIN ANTAGONIST, COMBINED WITH INDUCTION CHEMOTHERAPY IN ELDERLY PATIENTS WITH UNTREATED AML: A NOVEL, WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE
EHA Learning Center, Daniel J. DeAngelo, 181490
A PHASE 2 STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
EHA Learning Center, Jorge E. Cortes, 181491
CM942 IS A NEW SMALL MOLECULE THAT TARGETS SET-PP2A INTERACTION AND INHIBITS GROWTH OF ACUTE MYELOID LEUKEMIA CELLS
EHA Learning Center, Patricia García Ramírez, 181492
CLONAL HETEROGENEITY IN LEUKEMIC STEM CELLS FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Learning Center, Linda Manta, 181493
TREATMENT OF PRACINOSTAT AND AZACITIDINE IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): CORRELATION BETWEEN MUTATION CLEARANCE AND CLINICAL RESPONSE
EHA Learning Center, Elena Palmesino, 181494
STABLE DISEASE WITH HEMATOLOGIC IMPROVEMENT IS CLINICALLY MEANINGFUL FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE
EHA Learning Center, Andre C. Schuh, 181495
A RANDOMIZED PHASE II STUDY OF IDARUBICIN AND CYTARABINE WITH EITHER CLOFARABINE (CIA) OR FLUDARABINE (FIA) IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
EHA Learning Center, Nicholas Short, 181496
OVERALL SURVIVAL AND TRANSPLANTATION IN PATIENTS WITH FLT3 MUTATIONS: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE MYELOID LEUKEMIA
EHA Learning Center, Bruno Medeiros, 181497
NIVOLUMAB MAINTENANCE THERAPY FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML) IN REMISSION
EHA Learning Center, Tapan Kadia, 181498
HIGHER EXPRESSION OF LONG NON-CODING RNA KIAA0125 IS ASSOCIATED WITH CHARACTERISTIC CLINICAL AND BIOLOGICAL FEATURES AND IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Sheng-Yu Hung, 181499
LEUKEMIC STEM CELLS CAN BE DETECTED IN A CONSIDERABLE PERCENTAGE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AT DIAGNOSIS AND IS A SIGNIFICANT PROGNOSTIC FACTOR
EHA Learning Center, Olga Pérez-López, 181500
POST-REMISSIONAL AND PRE-TRANSPLANT ROLE OF MINIMAL RESIDUAL DISEASE DETECTED BY WT1 IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COHORT STUDY
EHA Learning Center, Chiara Frairia, 181501
DIFFERENTIATION SYNDROME ASSOCIATED WITH ENASIDENIB (AG-221), A SELECTIVE INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE 2 (MIDH2)
EHA Learning Center, Amir T. Fathi, 181502
OUTCOME OF PATIENTS WITH INTRAVASCULAR B-CELL LYMPHOMA, A RETROSPECTIVE STUDY CONDUCTED ON BEHALF OF THE LYMPHOMA STUDY ASSOCIATION (LYSA) GROUP
EHA Learning Center, Antoine BONNET, 181504
OUTCOME OF ELDERLY DLBCL PATIENTS (≥ 80 YEARS) TREATED WITH ANTHRACYCLINE BASED CHEMOTHERAPY; R-CHOP DOSE REDUCTION IS NOT NECESSARY FOR EVERYBODY
EHA Learning Center, Marek Trneny, 181505
IMPROVED SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) UP TO AGE 70 ONLY: A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL IN THE NETHERLANDS, 1989-2015
EHA Learning Center, Avinash Dinmohamed, 181506
CLINICAL CHARACTERISTICS AND LONG-TERM RESULTS OF TREATMENT OF DIFFUSE LARGE HEPATITIS C - ASSOCIATED NON-HODGKIN LYMPHOMA (DLBCL + C).
EHA Learning Center, Sergey Lepkov, 181507
Cardiac MR and 82 Rubidium PET for early detection of doxorubicin-induced cardiotoxicity in patients with malignant lymphoma
EHA Learning Center, Adam Høgsbro Laursen, 181508
RELAPSE CHARACTERISTICS AND THE ROLE OF SURVEILLANCE COMPUTED TOMOGRAPHY IN AGGRESSIVE NON-HODGKIN LYMPHOMA
EHA Learning Center, Ka-Won Kang, 181510
A MULTI-CENTER STUDY OF GLIDE CHEMOTHERAPY CONSOLIDATED WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED STAGE IV AND RELAPSED EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA PATIENTS
EHA Learning Center, Jie Ji, 181511
LONG TERM FOLLOW-UP OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS TREATED WITH IFOSFAMIDE, ETOPOSIDE, EPIRUBICIN / INTERMEDIATE METHOTREXATE AND AUTOLOGOUS STEM CELL TRANSPLANTATION
EHA Learning Center, Michal Sieniawski, 181512
IDENTIFICATION OF A NOVEL GERMLINE MECOM / EVI1 VARIANT THAT RUNS IN A PEDIGREE WITH RADIOULNAR SYNOSTOSIS AND AMEGAKARYOCYTIC THROMBOCYTOPENIA AND PREDISPOSES TO ADULT ONSET MYELOID MALIGNANCY
EHA Learning Center, Tim Ripperger, 181513
LOSS OF THE HOMOLOGOUS RECOMBINATION GENE RAD51 LEADS TO FANCONI ANEMIA-LIKE SYMPTOMS IN ZEBRAFISH
EHA Learning Center, Jan Botthof, 181514
A NOVEL TELOMERASE RNA COMPONENT (TERC) VARIANT IN A FAMILY WITH MACROCYTOSIS AND MILD VARIABLE CYTOPENIAS
EHA Learning Center, Claire Burney, 181515
GENERATION OF X-LINKED DYSKERATOSIS CONGENITA-LIKE HUMAN HEMATOPOIETIC STEM CELLS
EHA Learning Center, Guillermo Guenechea, 181516
STUDY OF EXTRACELLULAR VESICLES ROLES IN THE PATHOPHYSIOLOGY OF THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS DURING ECULIZUMAB TREATMENT: A PILOT PROSPECTIVE LONGITUDINAL CLINICAL STUDY
EHA Learning Center, Adeline Wannez, 181517
TELOMERE LENGTH SCREENING TRIGGERED BY CLINICAL SUSPICION FOR CLASSICAL AND/OR CRYPTIC DYSKERATOSIS CONGENITA -PROSPECTIVE RESULTS FROM THE AACHEN TELOMEROPATHY REGISTRY
EHA Learning Center, Fabian Beier, 181518
TRANSPLANTATION IN PATIENTS WITH ACQUIRED APLASTIC ANEMIA OVER THE AGE OF 40: MORTALITY HAS NOT BEEN REDUCED IN 2010-2015.
EHA Learning Center, Sabrina Giammarco, 181519
CLINICAL AND GENETIC DIVERSITY IN DIAMOND-BLACKFAN ANAEMIA: AN UPDATE FROM THE UNITED KINGDOM
EHA Learning Center, Deena Iskander, 181520
BONE MARROW FAILURE SECONDARY TO NOVEL/KNOWN PRIMARY IMMUNODEFICIENCY-RELATED MUTATIONS. A SINGLE CENTER ANALYSIS
EHA Learning Center, Maurizio Miano, 181521
COVERSIN, A NOVEL C5 COMPLEMENT INHIBITOR, FOR THE TREATMENT OF PNH: RESULTS OF A PHASE 2 CLINICAL TRIAL
EHA Learning Center, Anita Hill, 181522
GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Jennifer Brown, 181523
DIFFERENTIAL ENHANCER TRANSCRIPTION ASSOCIATED WITH RISK ALLELE GENOTYPE IN CLL
EHA Learning Center, Jennifer Brown, 181524
BIALLELIC TP53 GENE MUTATIONS DUE TO COPY-NEUTRAL LOSS OF HETEROZYGOSITY AND MONOALLELIC MUTATIONS IN ABSENCE OF 17P DELETION OCCUR IN CLL WITH COMPARABLE FREQUENCY
EHA Learning Center, Karla , 181525
INTERGRATED OLIGO/SNP ARRAY- AND NEXT GENERATION SEQUENCING BASED ANALYSIS IS REQUIRED TO DETERMINE TP53/17P STATUS IN CLL PATIENTS
EHA Learning Center, Marian Stevens-Kroef, 181526
CYTOGENETIC CLONAL EVOLUTION OCCURS AT THE TIME OF DISEASE PROGRESSION DURING IBRUTINIB THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL.
EHA Learning Center, Philip Thompson, 181527
LANDSCAPE OF SOMATIC MUTATIONS AND THEIR IMPACT ON RESPONSE AND OUTCOMES FROM LENALIDOMIDE-BASED THERAPIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
EHA Learning Center, Boyu Hu, 181528
HIGH THROUGHPUT IMMUNOPROFILING OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS ASSIGNED TO STEREOTYPED SUBSET #4: NOVEL INSIGHTS INTO THE DEPTH, DIVERSITY AND TEMPORAL DYNAMICS OF CLONAL EVOLUTION
EHA Learning Center, Lesley-Ann Sutton, 181529
FAILED HYDROXYMETHYLATION CONTRIBUTES TO A CHRONIC LYMPHOCYTIC LEUKEMIA SPECIFIC EPIGENOTYPE
EHA Learning Center, Katarzyna Szarc vel Szic, 181530
DNA METHYLATION PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CARRYING STEREOTYPED B-CELL RECEPTORS: A DIFFERENT CELLULAR ORIGIN FOR SUBSET #2?
EHA Learning Center, SUJATA BHOI, 181531
ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6 MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE BLOODWISE TAP ICICLLE EXTENSION STUDY
EHA Learning Center, Andrew Rawstron, 181532
CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPRESSING THE LIGHT CHAIN IGLV3-21 HAVE A POOR PROGNOSIS INDEPENDENTLY OF HEAVY CHAIN IGHV3-21 OR THE IGHV MUTATIONAL STATUS
EHA Learning Center, Basile Stamatopoulos, 181533
DURABILITY OF RESPONSES ON CONTINUOUS THERAPY AND FOLLOWING DRUG CESSATION IN DEEP RESPONDERS WITH VENETOCLAX AND RITUXIMAB
EHA Learning Center, Mary Ann Anderson, 181534
PREDICTIVE AND PROGNOSTIC IMPACT OF GENE MUTATIONS IN THE CONTEXT OF FLUDARABINE AND CYCLOPHOSPHAMIDE (FC) WITH OR WITHOUT OFATUMUMAB TREATMENT IN PATIENTS WITH REL/REF CLL
EHA Learning Center, Eugen Tausch, 181535
RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
EHA Learning Center, Alexey Danilov, 181536
RELATIVE SURVIVAL REACHES A PLATEAU IN HAIRY CELL LEUKEMIA (HCL): A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL AMONG 1,427 PATIENTS DIAGNOSED IN THE NETHERLANDS, 1989-2014
EHA Learning Center, Avinash Dinmohamed, 181537
CUMULATIVE ILLNESS RATING SCALE (CIRS) PROVIDES PROGNOSTIC INFORMATION BEYOND THE INTERNATIONAL PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI): AN ACROSS-TRIAL ANALYSIS BY THE GCLLSG
EHA Learning Center, Valentin Goede, 181538
A PHASE II RANDOMISED STUDY INVESTIGATING THE EFFICACY OF STANDARD OR HIGH-DOSE OFATUMUMAB IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA
EHA Learning Center, david allsup, 181539